secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2024-10-16T23:59:59+00:00
Accession:  0001664710-24-000081
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics appoints Yung H. Chyung as Chief Medical Officer
-------------------------------------------------------------------

- Dr. Chyung appointed Chief Medical Officer effective November 1, 2024, succeeding Simon Cooper.
- He will receive an annual base salary of $510,000 and a target bonus of 40% of base salary.
- Eligible for a stock option to purchase 110,000 shares vesting over four years.
- Previously Executive VP and CMO at Tourmaline Bio (2022-2024) and CMO at Scholar Rock (2016-2022).
- Company press release issued October 16, 2024, announcing the appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000081/0001664710-24-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000081/kros-20241015.htm
  HTML page:      https://secwatch.observer/filing/0001664710-24-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer